文献速递心力衰竭与心肌病瓣膜病与结构性心脏病

心脏移植后排斥监测:心血管磁共振可行

Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation.
PubMed 文献 · Circulation · 2022-05-27

本研究旨在评估心脏移植后第一年使用心血管磁共振(CMR)监测急性心脏移植物排斥(ACAR)的可行性。结果显示CMR检测ACAR的曲线下面积为0.92,敏感性93%,特异性92%,阴性预测值99%;CMR组住院率和感染率更低,且EMB需求减少94%。

要点

  • CMR多参数评估检测ACAR的AUC为0.92,敏感性93%,特异性92%,阴性预测值99%。
  • 随机分组中CMR组与EMB组高级别排斥发生率相似(7 vs 8,P=0.74)。
  • CMR组住院率(45% vs 90%)和感染率(35% vs 70%)均低于EMB组。

核心结论

  • 基于CMR的无创监测策略在心脏移植后第一年监测ACAR是可行的,与基于EMB的监测相比具有可行性。

研究设计与样本

  • 研究首先采用前瞻性横断面设计评估CMR多参数映射与EMB诊断ACAR的一致性并确定CMR截断值。
  • 随机分组在心脏移植后4周进行,分为CMR或EMB监测组,临床终点在52周评估。

主要发现

  • CMR多参数评估检测ACAR的曲线下面积为0.92,敏感性93%,特异性92%,阴性预测值99%,其特异性和阴性预测值高于单独T1或T2参数映射。
  • 随机分组中CMR组高级别排斥7例,EMB组8例(P=0.74),两组免疫抑制需求、肾功能和死亡率相似。
  • CMR组住院率45%(9/20)低于EMB组90%(18/20),比值比0.091,P=0.006。
  • 随机至CMR组的患者中有15次(6%)因澄清或后勤原因接受EMB,代表EMB监测需求减少94%。

关键数值与推荐

  • CMR检测ACAR的截断值在横断面研究中确定,但原文未报告具体数值。
  • CMR多参数评估检测ACAR的AUC为0.92,敏感性93%,特异性92%,阴性预测值99%。
  • 随机分组中高级别排斥发生率CMR组7例 vs EMB组8例,P=0.74。

临床怎么用

  • 对于心脏移植后第一年的受者,可考虑使用基于CMR的无创监测策略替代部分EMB监测。
  • CMR多参数评估具有高阴性预测值,有助于排除ACAR。
  • 采用CMR监测可能降低住院率和感染率,并大幅减少EMB需求。

局限性

  • 原文未报告CMR截断值具体数值。
  • 研究仅针对心脏移植后第一年,长期可行性未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Endomyocardial biopsy (EMB) is the gold standard method for surveillance of acute cardiac allograft rejection (ACAR) despite its invasive nature. Cardiovascular magnetic resonance (CMR)-based myocardial tissue characterization allows detection of myocarditis. The feasibility of CMR-based surveillance for ACAR-induced myocarditis in the first year after heart transplantation is currently undescribed. METHODS: CMR-based multiparametric mapping was initially assessed in a prospective cross-sectional fashion to establish agreement between CMR- and EMB-based ACAR and to determine CMR cutoff values between rejection grades. A prospective randomized noninferiority pilot study was then undertaken in adult orthotopic heart transplant recipients who were randomized at 4 weeks after orthotopic heart transplantation to either CMR- or EMB-based rejection surveillance. Clinical end points were assessed at 52 weeks. RESULTS: Four hundred one CMR studies and 354 EMB procedures were performed in 106 participants. Forty heart transplant recipients were randomized. CMR-based multiparametric assessment was highly reproducible and reliable at detecting ACAR (area under the curve, 0.92; sensitivity, 93%; specificity, 92%; negative predictive value, 99%) with greater specificity and negative predictive value than either T1 or T2 parametric CMR mapping alone. High-grade rejection occurred in similar numbers of patients in each randomized group (CMR, n=7; EMB, n=8; P=0.74). Despite similarities in immunosuppression requirements, kidney function, and mortality between groups, the rates of hospitalization (9 of 20 [45%] versus 18 of 20 [90%]; odds ratio, 0.091; P=0.006) and infection (7 of 20 [35%] versus 14 of 20 [70%]; odds ratio, 0.192; P=0,019) were lower in the CMR group. On 15 occasions (6%), patients who were randomized to the CMR arm underwent EMB for clarification or logistic reasons, representing a 94% reduction in the requirement for EMB-based surveillance. CONCLUSIONS: A noninvasive CMR-based surveillance strategy for ACAR in the first year after orthotopic heart transplantation is feasible compared with EMB-based surveillance. REGISTRATION: HREC/13/SVH/66 and HREC/17/SVH/80. AUSTRALIAN NEW ZEALAND CLINICAL TRIALS REGISTRY: ACTRN12618000672257.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Anthony C, Imran M, Pouliopoulos J, et al. Cardiovascular Magnetic Resonance for Rejection Surveillance After Cardiac Transplantation. Circulation. 2022. PMID: 35621277. doi:10.1161/CIRCULATIONAHA.121.057006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。